TriRx hosts various leaders at a ribbon-cutting ceremony for their new facility.
TriRx Pharmaceutical Services hosted various state and community leaders at the ribbon-cutting ceremony celebrating the acquisition of their Shawnee, Kan. facility. In attendance were state and local government officials.
The Shawnee facility was acquired from Elanco Animal Health Incorporated on August 1, 2021. They also entered into a long-term supply agreement which will assure a reliable supply of Elanco products.
Dave Urbanek, executive vice president of manufacturing and quality for Elanco, attended the ceremony to officially grant ownership to Timothy C. Tyson, chairman and CEO of TriRx. He also thanked Elanco employees for their continuous contributions and support.
The facility, which employs approximately 300 individuals, can make parenterals, topicals, non-sterile liquids, solid oral dose, and soft chews. It features a pilot plant, quality control laboratories, veterinary technical services, and a large warehousing and distribution facility.
"We are looking forward to increasing the capabilities and efficiencies of this site’s operations,” said Tyson in a company press release. “The journey ahead will bring prosperity to TriRx, TriRx team members and stakeholders, and the broader Shawnee community. This site will represent a highly valued addition to the TriRx capabilities to continue to serve the rapidly expanding global biopharmaceutical market.”
Source: TriRx
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Telix Enters Agreement with ImaginAb to Purchase Next-Gen Therapeutic Candidates
Published: January 13th 2025 | Updated: January 13th 2025The transaction adds a pipeline of early-stage drug candidates against high-value targets to Telix’s portfolio, along with other novel targets currently in the discovery stage.